oncology startup ottimo pharma emerges with innovative dual-pathway cancer drug

A new oncology startup called Ottimo Pharma has been launched by David Epstein, the former CEO of Seagen.

Ottimo Pharma's Mission

The company aims to develop a novel drug that targets two critical molecular pathways involved in tumor growth and immune evasion: PD-1 and VEGF.

Backed by Medicxi

Ottimo Pharma has received backing from the U.K. venture firm Medicxi and plans to seek regulatory approval for its first clinical trial in the near future.

Dual-Targeting Strategy

The company's approach involves the development of a bi-functional antibody called jankistomig, which inhibits both PD-1 and the VEGF receptor VEGFR2.

This dual targeting strategy aims to minimize side effects associated with VEGF inhibition.

A Broader Trend in Oncology

Ottimo Pharma's innovative approach reflects a broader trend in oncology, where researchers are exploring the synergies of targeting multiple pathways to improve patient outcomes.

Other companies, such as BioNTech and Instil Bio, are also developing similar dual-targeting drugs.

Experienced Leadership Team

The leadership team of Ottimo Pharma includes industry veterans with extensive experience in the field.

Revolutionizing Cancer Treatment

The company's strategic vision is to revolutionize cancer treatment through dual-pathway targeting and deliver on the promise of new therapies for patients.

Implications for the Future

The success of Ottimo Pharma's approach could have significant implications for the future of cancer immunotherapy and patient care.

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings